Activin-a signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer

npj Breast Cancer

Volumn 1, Issue , 2015, Pages

  Bashir, Mohsin ^a   Damineni, Surekha ^a   Mukherjee, Geetashree ^b   Kondaiah, Paturu ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84992039419     PISSN: None     EISSN: 23744677     Source Type: Journal    
DOI: 10.1038/npjbcancer.2015.7     Document Type: Article

References (45)

1. Wakefield LM, Hill CS. Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer 2013; 13: 328–341.
2. Rivier C, Vale W, Rivier J. Studies of the inhibin family of hormones: a review. Horm Res 1987; 28: 104–118.
3. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008; 55: 11–21.
4. Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 1986; 321: 779–782.
5. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986; 321: 776–779.
6. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R et al. Functional analysis of activins during mammalian development. Nature 1995; 374: 354–356.
7. Totsuka Y, Tabuchi M, Kojima I, Shibai H, Ogata E. A novel action of activin A: stimulation of insulin secretion in rat pancreatic islets. Biochem Biophys Res Commun 1988; 156: 335–339.
8. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 2008; 105: 7082–7087.
9. Dunphy KA, Schneyer AL, Hagen MJ, Jerry DJ. The role of activin in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 2011; 16: 117–126.
10. Chen Y-G, Lui HM, Lin S-L, Lee JM, Ying S-Y. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med Maywood NJ 2002; 227: 75–87.
11. Beattie GM, Lopez AD, Bucay N, Hinton A, Firpo MT, King CC et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 2005; 23: 489–495.
12. Robson NC, Phillips DJ, McAlpine T, Shin A, Svobodova S, Toy T et al. Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 2008; 111: 2733–2743.
13. Kang H-Y, Huang H-Y, Hsieh C-Y, Li C-F, Shyr C-R, Tsai M-Y et al. Activin a enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J Bone Min Res 2009; 24: 1180–1193.
14. Wildi S, Kleeff J, Maruyama H, Maurer C, Buchler M, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001; 49: 409–417.
15. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma1. Neoplasia 2009; 11: 388–396.
16. Deli A, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W et al. Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1699–1709.
17. Lonardo E, Hermann PC, Mueller M-T, Huber S, Balic A, Miranda-Lorenzo I et al. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433–446.
18. Yoshinaga K, Yamashita K, Mimori K, Tanaka F, Inoue H, Mori M. Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol 2008; 15: 96–103.
19. Antsiferova M, Huber M, Meyer M, Piwko-Czuchra A, Ramadan T, MacLeod AS et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun 2011; 2: 576.
20. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994; 91: 8817–8821.
21. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531–543.
22. Fordyce Ca, Patten KT, Fessenden TB, Defilippis R, Hwang ES, Zhao J et al. Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res 2012; 14: R155.
23. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 2003; 63: 3783–3790.
24. Reis FM, Luisi S, Carneiro MM, Cobellis L, Federico M, Camargos AF et al. Activin, inhibin and the human breast. Mol Cell Endocrinol 2004; 225: 77–82.
25. Candia AF, Watabe T, Hawley SH, Onichtchouk D, Zhang Y, Derynck R et al. Cellular interpretation of multiple TGF-beta signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 1997; 124: 4467–4480.
26. Luo Y-J, Su Y-H. Opposing nodal and BMP signals regulate left-right asymmetry in the sea urchin larva. PLoS Biol 2012; 10: e1001402.
27. Thompson EW, Newgreen DF. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991–5995.
28. Lu S, Lee J, Revelo M, Wang X, Dong Z. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007; 13: 5692–5702.
29. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010; 70: 968–978.
30. Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, Céspedes MV et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012; 22: 571–584.
31. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–549.
32. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001; 7: 2931–2940.
33. Zhang Y, Toy K a, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 2012; 25: 178–184.
34. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62–73.
35. Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008; 3: 196–206.
36. Djouad F, Jackson WM, Bobick BE, Janjanin S, Song Y, Huang GT et al. Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem Cell Res Ther 2010; 1: 11.
37. Yang Y-L, Liu Y-S, Chuang L-Y, Guh J-Y, Lee T-C, Liao T-N et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology 2009; 150: 727–740.
38. Phillips AO, Fraser DJ. BMP-7 stops TGF-β in peritoneal fibrosis. Nephrol Dial Transplant 2010; 25: 1036–1038.
39. Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2012; 31: 2164–2174.
40. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–352.
41. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006; 23: 117–122.
42. Ottley E, Gold E. Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression. Cytokine Growth Factor Rev 2012; 23: 119–125.
43. Padua D, Massagué J. Roles of TGFβ in metastasis. Cell Res 2009; 19: 89–102.
44. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.
45. Hu Z, Gerseny H, Zhang Z, Chen Y-J, Berg A, Zhang Z et al. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther 2011; 19: 1609–1618.